Home » Stocks » Pandion Therapeutics

Pandion Therapeutics, Inc. (PAND)

Stock Price: $19.11 USD 0.61 (3.30%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 545.13M
Revenue (ttm) 2.97M
Net Income (ttm) n/a
Shares Out 28.53M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $19.11
Previous Close $18.50
Change ($) 0.61
Change (%) 3.30%
Day's Open 18.31
Day's Range 18.25 - 19.47
Day's Volume 101,022
52-Week Range 16.67 - 27.75

More Stats

Market Cap 545.13M
Enterprise Value 478.77M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 28.53M
Float 251,264
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 183.67
PB Ratio 8.52
Revenue 2.97M
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 66.36M
Net Cash / Share 2.33
Gross Margin 32.58%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit0.97-
Operating Income-22.22-11.05
Net Income-21.88-10.89
Shares Outstanding1.030.78
Earnings Per Share-25.00-17.00
Operating Cash Flow-13.43-10.61
Capital Expenditures-0.64-0.64
Free Cash Flow-14.06-11.24
Cash & Equivalents15.9710.17
Total Debt3.682.01
Net Cash / Debt12.298.16
Book Value-42.79-17.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pandion Therapeutics, Inc.
Country United States
Employees 43
CEO Rahul Kakkar

Stock Information

Ticker Symbol PAND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PAND
IPO Date July 17, 2020


Pandion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, an effector module comprised of an engineered variant of wild-type interleukin-2 (IL-2) fused to a protein backbone that is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company's other product candidates comprise PT627, a systemic PD-1 agonist that is in preclinical studies for the treatment of autoimmune diseases; PT001, a bifunctional molecule combining its PD-1 agonist effector with a tether module that binds to mucosal vascular addressing cell adhesion molecule (MAdCAM) to drive tissue-selective immunomodulation in the gastrointestinal tract; and PT002, a bifunctional molecule combining its IL-2 mutein effector with a tether module that binds to MAdCAM to drive tissue-selective immunomodulation in the gastrointestinal tract. It has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.